News | June 11, 2014

Dutch Cancer Patients to Benefit From Erasmus Medical Center's New Linacs

Largest medical center in the Netherlands upgrades with several Elekta Versa HD linear accelerators

June 11, 2014 — Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands, announced the purchase of Elekta Versa HD linear accelerators (linacs) and a software upgrade including the Mosaiq oncology information system (OIS) and Monaco 5 treatment planning system.

The advanced Versa HD linac system is designed to improve patient care and treat a broad spectrum of cancers. Its high precision and unique beam shaping technology increases tumor targeting, with the aim of delivering better outcomes for cancer patients.

According to Comprehensive Cancer Centre the Netherlands (IKNL), approximately 100,000 people are diagnosed with cancer in the Netherlands annually. Many of them are treated at Erasmus MC, while linacs at Albert Schweitzer hospital, a satellite in Dordrecht, will also be upgraded.

Luca Incrocci, associate professor of radiation oncology at Erasmus MC, said, "Our history of research and collaboration with Elekta means we know we are receiving commitment and quality. Elekta's equipment and solutions will help us to fulfill our vision of being a recognized leader in treating patients with cancer and to meet our goal to develop research programs to improve treatment results and the quality of life of our patients. "

"Erasmus and Elekta have had a collaborative relationship that goes back 10 years," said Thijs van Bommel, business unit manager for the Netherlands at Elekta AB. "They share our pioneering spirit and focus on patient care, education and scientific research. This mindset helped them easily understand the benefits of Elekta solutions including Versa HD, a flexible and integrated treatment system."

For more information: www.elekta.com

Related Content

With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.
RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a new modality that will one day treat all stages of cancer,announced the sale of its RefleXion X1 machine to The Center for Cancer and Blood Disorders, a free-standing cancer treatment center with 15 locations throughout northern Texas.

RefleXion Medical announces the sale of its X1 machine to The Center for Cancer and Blood Disorders in Texas. (Photo: Business Wire)

News | Radiation Therapy | August 23, 2021
August 23, 2021 — ...
The global radiotherapy market is forecasted to reach USD 7987.01 Million in the year 2020, according to the "Global Radiotherapy Market - Analysis By Procedure (External Radiation, Internal Radiation), Product, Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)" report from ResearchAndMarkets.com
News | Radiation Therapy | August 20, 2021
August 20, 2021 — The global radiotherapy market is forecasted to reach $8.29 billion in the year 2021, according to